Trastuzumab (Herceptin) – anti-HER2 treatment review for selected HER2 tumors

What trastuzumab is in simple patient language

Herceptin is the brand name. Trastuzumab is the drug name in the medical file. An antibody treatment. Not classic chemotherapy. Not a tablet. Not a drug to start just because the word HER2 appears somewhere in a report.

The first step is the HER2 result. Without that result, the drug has no clear target. The doctor needs to see how HER2 was tested, what the tumor type is, and where this treatment would sit in the whole plan.

For the patient, the question is plain. Why this drug, why now, and with what other treatment? A plan after surgery is different from a plan for metastatic disease. A breast cancer plan is not the same as a stomach cancer plan. Heart strength also matters before the first infusion.

How trastuzumab works

Some cancer cells carry a lot of HER2 on their surface. HER2 can act like a loud growth signal. The cell keeps hearing “grow” and “divide” more than it should.

Trastuzumab attaches to HER2. In simple words, it tries to make that signal harder for the tumor cell to use. It can also help the immune system notice cells that carry HER2.

That is only one part of the story. The oncologist still has to place the drug in a real treatment route: before surgery, after surgery, together with chemotherapy, with hormone treatment in selected cases, or later in metastatic disease.

The heart is part of the same discussion. Trastuzumab can be very useful, but the heart cannot be ignored. The file needs a baseline heart check and a plan for follow-up.

Which diseases or situations trastuzumab may be used for

Trastuzumab belongs in a HER2-driven discussion. The tumor name alone does not choose it. The HER2 test has to support the plan.

• breast cancer where HER2 is clearly driving the treatment choice
• early breast cancer, when Herceptin is part of the plan around surgery and other treatment
• metastatic breast cancer, when body-wide HER2 treatment is needed
• some stomach or food-pipe junction tumors where HER2 changes the drug plan
• a second opinion when Herceptin, a biosimilar, or another HER2 drug was offered
• situations where the main question is whether the heart can safely carry the plan

Two people can have the same HER2 word and still need different routes. Stage, old treatment, heart tests, symptoms, and the goal of treatment change the answer.

When trastuzumab can be especially relevant

Herceptin comes up when HER2 is not just a note in the biopsy. It has to be part of the reason for the treatment plan.

• the HER2 result is strong enough for HER2-directed therapy
• the doctor is building treatment before or after surgery
• the disease has spread and needs treatment through the whole body
• another HER2 medicine is being compared with Herceptin
• the patient had older treatment and the next HER2 step is unclear
• heart safety is the main worry before continuing or restarting treatment

The useful question is not “is Herceptin famous?” It is more practical: what is this course meant to do now, and can the patient go through it safely?

What needs to be checked before treatment

A short note with the cancer name is not enough. The oncologist needs the real file, not only a label.

• the biopsy report and the exact tumor type
• HER2 testing, including the method and result
• ER and PR results in breast cancer, if they were checked
• stage, scans, and the reason treatment is being planned now
• all previous cancer drugs, with dates and the reason they stopped
• heart ultrasound or another heart function check
• blood pressure, breathlessness, swelling, rhythm complaints, or past heart disease
• blood work and chemistry tests, when they are part of the plan
• past infusion reactions, allergies, or difficult reactions to antibodies
• the full medicine list, including heart pills, pressure pills, pain pills, and supplements

The heart check is not a side detail. It can change timing, dose decisions, and whether a cardiologist should be involved before the next infusion.

How treatment with trastuzumab goes

Trastuzumab is usually given in a clinic or day unit. The schedule comes from the oncologist. The patient does not change dates, skip infusions, or restart old treatment by guess.

The way it is used depends on the disease setting. Sometimes it runs with chemotherapy. Sometimes it continues after chemotherapy has ended. In metastatic disease, the team keeps asking whether the current route is still helping enough.

During treatment, the team usually follows:

• how the patient feels during and after the infusion
• shivering, feverish feeling, rash, itching, or sudden discomfort during treatment
• breathing changes, new swelling, chest pressure, or rhythm changes
• heart function over time
• side effects from the other drugs in the same plan
• blood tests, if chemotherapy or another drug makes them needed
• scans or other checks used to judge the cancer response

A pause for a heart test does not always mean the drug is finished. Sometimes it is a safety stop. The next step depends on the heart result, the cancer situation, and the symptoms.

Possible side effects

Many people do not feel the same side effects from trastuzumab. Some problems come from the partner drugs, not from Herceptin alone. This is why the whole plan has to be read together.

• shivering, feverish feeling, tiredness, or body aches around the infusion
• rash, itching, redness, or skin discomfort
• nausea, loose stool, poor appetite, or headache
• cough, lighter breathing capacity, or new effort with stairs
• leg swelling, fast heartbeat, chest pressure, or weaker exercise tolerance
• blood count changes when chemotherapy is part of the same plan
• rare strong reactions during the infusion or later

The patient does not need to expect every problem. The point is to speak early when something feels new, especially if it involves breathing, swelling, the chest, or an infusion reaction.

When the treating team needs to know fast

Call or message the treating team the same day if any of these starts:

• new trouble breathing, or breathing that is getting worse
• swelling in the legs or face, sudden heavy tiredness, or not managing normal walking
• pressure, pain, or tight feeling in the chest
• fainting, strong dizziness, or a racing heartbeat
• a strong reaction during infusion: shaking, heat, rash, itching, throat tightness, or sudden weakness
• rash that spreads quickly or swelling around the face
• repeated vomiting, severe loose stool, or not being able to drink
• any fast drop in the patient’s general condition

Do not try to decide at home whether Herceptin caused it. The team can sort that out. The patient needs help before a small warning becomes a bigger problem.

Why trastuzumab is not right for everyone

Trastuzumab can be a key drug in the right HER2 case. It is still not automatic.

• HER2 was not confirmed, or the result is not clear
• the biopsy may need another review
• heart function is too weak for the planned course
• heart function fell during older treatment
• there was a severe infusion reaction in the past
• the patient is too unwell for the planned combination
• another HER2 drug fits the current line better

Not using Herceptin does not mean the drug is bad. It may be the wrong time, the wrong line, or too risky until the heart question is settled.

Can trastuzumab be combined with other treatments

Yes. In many plans, trastuzumab is not alone. The partner drugs depend on the tumor type, stage, older treatment, and the goal of the current course.

• with chemotherapy in selected breast cancer or stomach cancer plans
• with another HER2-directed drug, when the route calls for it
• with hormone treatment in some breast cancer plans
• after surgery, or around other treatment stages
• after radiation or local treatment, if the wider plan is built that way
• in a sequence after older HER2 drugs, if the disease has changed

More drugs do not automatically mean a better plan. The doctor has to know what each part is doing and what each part may add to the body.

What no quick response can mean

With trastuzumab, the patient may not feel a quick effect. After surgery, the goal may be to lower the chance of the disease returning. The patient can feel well and still need the course.

In metastatic disease, the answer usually comes from scans, symptoms, blood work when needed, and how the patient gets through treatment. Sometimes the tumors shrink. Sometimes the useful result is a calmer disease for a time.

The review date should be clear from the beginning. The patient should know when the team will check the result, and what would make them continue, pause, or change the route.

Oncology consultation in Israel about trastuzumab

At Tel Aviv Medical Clinic, Herceptin can be discussed as part of a second opinion for HER2-related breast cancer or selected stomach-area tumors. This can help when the patient has a recommendation but does not fully understand the reason for the drug or the heart checks.

The consultation can help clarify:

• whether the HER2 result is enough for this plan
• where Herceptin fits: before surgery, after surgery, or in metastatic disease
• which partner drugs are being used and why
• how the heart will be followed
• whether a biosimilar or another HER2 drug is being discussed
• which documents are missing before a clean answer
• which questions should go back to the treating oncologist

We do not prescribe treatment remotely and we do not replace the treating doctor. The purpose is to organize the case and make the next medical conversation clearer.

Frequently asked questions – answered by Dr. Stefanska

1. Is Herceptin chemotherapy?

No. Herceptin is not classic chemotherapy. It is an antibody drug aimed at HER2.

That does not make it a casual treatment. The patient still needs a plan, infusion monitoring, and heart follow-up. Also, many patients receive Herceptin with chemotherapy, so the side effects may come from the full scheme, not from one drug alone.

2. Why is the HER2 test so important?

Because without HER2, Herceptin has no clear job. The cancer name is not enough.

I want to see the report itself: how HER2 was checked, whether the result is strong or borderline, and whether another test is needed. If the result is old or unclear, the first step may be to review the material again.

3. Why does the doctor check the heart before treatment?

Because Herceptin can affect heart function in some patients. This is more important if the patient already has heart disease or had older drugs that can stress the heart.

A heart check before treatment gives the team a starting point. If breathlessness, swelling, strong weakness, or heartbeat changes appear later, the doctor has something to compare with.

4. Can treatment continue if the heart test becomes worse?

Sometimes yes. Sometimes no. It depends on how much the result changed and whether the patient has symptoms.

I would not decide this from one number alone. I would look at the cancer situation, the old treatment, the heart history, and the cardiology opinion. The aim is not to stop too fast or continue blindly. The aim is to keep the plan safe.

5. Is Herceptin always given with chemotherapy?

No. It can be given with chemotherapy in some stages. It can also continue after chemotherapy is finished. In other cases it may be used with another HER2 drug or with hormone treatment.

So the real question is the setting. Is this after surgery? Is the disease metastatic? Was HER2 treatment already used? The answer changes the schedule and the partner drugs.

6. What should I do if I feel bad during an infusion?

Tell the nurse or doctor right away. Do not sit quietly and wait for it to pass.

Shaking, heat, rash, itching, chest pressure, throat tightness, or sudden breath trouble all need attention. The team may slow the infusion, stop it for a while, give medicine, or change the next visit plan. Early warning makes this easier to handle.

7. What should be sent for a second opinion about Herceptin?

Send the biopsy report, the HER2 test, ER and PR results if this is breast cancer, the latest scans, the treatment list with dates, and the heart tests. Add notes about infusion reactions or heart problems.

A short timeline helps a lot: when the diagnosis was made, what was already given, what worked, what stopped working, and why Herceptin is being discussed now.

Important information

This page helps with general understanding. It is not a treatment prescription. Trastuzumab should be discussed only after the doctor reviews the diagnosis, HER2 result, stage, heart function, older treatment, other medicines, and the patient’s condition.

Do not start, stop, or change treatment without the treating doctor.

Contacts

For a consultation about Trastuzumab:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108